Joe has covered a wide range of biopharmaceutical stories since 2007 and contributes to Scrip, In Vivo, Pink Sheet and related Citeline publications. His specialties include business development, commercial strategies and liver and infectious diseases.
Latest from Joseph Haas
Deal snapshot: The Flagship portfolio firm will use its Decode platform to seek novel targets for an unspecified autoimmune disease, with Genentech holding license rights.
The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.
Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.
Plus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.
Cancer assets drove the highest percentage of biopharma alliance dealmaking in 2024, tripling the frequency of the next highest therapeutic category, neurology.
Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.